Praxis Precision Medicines (NASDAQ:PRAX) Price Target Raised to $28.00

Praxis Precision Medicines (NASDAQ:PRAX) had its target price hoisted by Wedbush from $26.00 to $28.00 in a report released on Monday morning,Benzinga reports. The firm currently has an underperform rating on the stock. Wedbush also issued estimates for Praxis Precision Medicines’ Q2 2025 earnings at ($2.94) EPS, Q3 2025 earnings at ($2.87) EPS, Q4 2025 earnings at ($2.69) EPS, FY2025 earnings at ($11.79) EPS, Q1 2026 earnings at ($1.98) EPS, Q2 2026 earnings at ($2.01) EPS, Q3 2026 earnings at ($2.03) EPS, Q4 2026 earnings at ($2.06) EPS, FY2026 earnings at ($8.08) EPS, FY2027 earnings at ($6.71) EPS, FY2028 earnings at ($5.38) EPS and FY2029 earnings at ($4.37) EPS.

A number of other equities research analysts also recently commented on PRAX. Needham & Company LLC reaffirmed a “buy” rating and set a $80.00 target price on shares of Praxis Precision Medicines in a report on Monday. Robert W. Baird decreased their price objective on shares of Praxis Precision Medicines from $117.00 to $73.00 and set an “outperform” rating for the company in a research note on Monday, March 3rd. Truist Financial cut their price objective on shares of Praxis Precision Medicines from $175.00 to $85.00 and set a “buy” rating on the stock in a research note on Monday, March 3rd. HC Wainwright restated a “buy” rating and set a $105.00 target price on shares of Praxis Precision Medicines in a research report on Thursday, May 1st. Finally, Deutsche Bank Aktiengesellschaft assumed coverage on Praxis Precision Medicines in a research report on Tuesday, February 11th. They set a “buy” rating and a $111.00 price target on the stock. One analyst has rated the stock with a sell rating and nine have assigned a buy rating to the stock. According to data from MarketBeat.com, Praxis Precision Medicines presently has a consensus rating of “Moderate Buy” and an average price target of $116.50.

Praxis Precision Medicines Trading Up 8.3 %

Shares of Praxis Precision Medicines stock opened at $38.09 on Monday. Praxis Precision Medicines has a 12-month low of $26.70 and a 12-month high of $91.83. The firm’s 50 day simple moving average is $35.49 and its two-hundred day simple moving average is $61.39. The firm has a market capitalization of $775.86 million, a price-to-earnings ratio of -3.70 and a beta of 2.65.

Praxis Precision Medicines (NASDAQ:PRAX) last released its earnings results on Friday, May 2nd. The company reported ($3.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($3.20) by ($0.09). Praxis Precision Medicines had a negative net margin of 9,409.22% and a negative return on equity of 54.86%. On average, sell-side analysts predict that Praxis Precision Medicines will post -10.22 EPS for the current fiscal year.

Institutional Trading of Praxis Precision Medicines

Several institutional investors have recently bought and sold shares of the business. CIBC Asset Management Inc lifted its stake in Praxis Precision Medicines by 47.3% in the 4th quarter. CIBC Asset Management Inc now owns 366,756 shares of the company’s stock valued at $28,226,000 after buying an additional 117,817 shares in the last quarter. Barclays PLC lifted its position in shares of Praxis Precision Medicines by 126.8% in the third quarter. Barclays PLC now owns 37,130 shares of the company’s stock valued at $2,136,000 after acquiring an additional 20,759 shares in the last quarter. Franklin Resources Inc. boosted its stake in shares of Praxis Precision Medicines by 85.6% in the third quarter. Franklin Resources Inc. now owns 445,233 shares of the company’s stock worth $25,619,000 after acquiring an additional 205,335 shares during the last quarter. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Praxis Precision Medicines during the fourth quarter worth approximately $304,000. Finally, Vanguard Group Inc. raised its stake in Praxis Precision Medicines by 2.4% in the 4th quarter. Vanguard Group Inc. now owns 1,063,639 shares of the company’s stock valued at $81,858,000 after purchasing an additional 24,645 shares during the last quarter. 67.84% of the stock is owned by institutional investors and hedge funds.

Praxis Precision Medicines Company Profile

Praxis Precision Medicines, Inc, a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy.